Order Article Reprints

Buonadonna A, Scalone S, Lombardi D, Fumagalli A, Guglielmi A, Lestuzzi C, Polesel J, Canzonieri V, Lamon S, Giovanis P, et al. Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas. Cancers. 2023; 15(20):5036. https://doi.org/10.3390/cancers15205036

Buonadonna, Angela, Simona Scalone, Davide Lombardi, Arianna Fumagalli, Alessandra Guglielmi, Chiara Lestuzzi, Jerry Polesel, Vincenzo Canzonieri, Stefano Lamon, Petros Giovanis, and et al. 2023. "Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas" Cancers 15, no. 20: 5036. https://doi.org/10.3390/cancers15205036

Buonadonna, A., Scalone, S., Lombardi, D., Fumagalli, A., Guglielmi, A., Lestuzzi, C., Polesel, J., Canzonieri, V., Lamon, S., Giovanis, P., Gagno, S., Corona, G., Mascarin, M., Belluco, C., De Paoli, A., Fasola, G., Puglisi, F., & Miolo, G. (2023). Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas. Cancers, 15(20), 5036. https://doi.org/10.3390/cancers15205036